EGFR and neoplasm: Interestingly, RAS mutations were mostly detected in patients who presented stable disease as best response with a shorter duration of response (mPFS of 25.6 weeks), compared to EGFR-ECD mutations which were more frequently detected in patients achieving a higher decrease in tumor size (partial response) and a longer duration of response (mPFS of 44.6 weeks).